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C3 Glomerulonephritis versus “C3 Glomerulopathies?”
T. Keefe Davis M.D., FAAP

Background and epidemiology
C3 glomerulonephritis (C3Gn) is a due to abnormal regulation of the alternative
complement pathway. The diagnosis is based upon kidney biopsy immunofluorescences
studies showing isolated or dominant C3 deposition within the glomerulus with little or no
immunoglobulin deposition.1 It is a distinct entity from the other 4 classes of glomerulonephritis
(Gn): immune complex, pauci-immune, antiglomerular basement membrane antibody, and
monoclonal Gn.2 One caveat to immune complex disease is that there is a subset of patients
with atypical post infectious glomerulonephritis who have persistent lab abnormalities (low C3,
proteinuria, or elevated creatinine). Patients with an atypical post infectious course may have
C3Gn.
The cause of C3Gn is excessive activation of the alternative complement pathway. The
primary defect is increased activity of the C3 and C5 convertases.3 One mechanism underlying
the increased activity of these convertases is the development of a stabilizing autoantibody
called C3 nephritic factor (C3NF). Indeed, C3 nephritic factor hinders the breakdown of C3
convertase, allowing it to continue to amplify the cascade resulting in increased production of
C3 and by also generating the C5 convertase which itself initiates the membrane attack
complex.4 The other mechanism responsible for increased activity of the C3 convertase is the
loss of factor H functionality. Since the normal function of factor H is to inhibit the C3
convertase, mutations or acquired loss of the ability of factor H to regulate activated C3 results
in excessive convergence towards assembly of the membrane attack complex.4

C3 glomerulonephritis is a pediatric disease and rates of diagnosis are increasing with greater
awareness of this distinct and separate entity from dense deposit disease (DDD), both of which
are commonly classified under the broad heading of C3 glomerulopathies (Table 1).3,5,6
Unfortunately, the classification of both C3Gn and DDD as C3 glomerulopathies adds confusion
to the classification schema due to subtleties in the nomenclature.
Table 1. C3 Glomerulopathies: Comparing and Contrasting Dense Deposit Disease versus C3
Glomerulonephritis.
Descriptive Factor

Dense Deposit Disease

C3 Glomerulonephritis

Pathophysiology

Abnormal regulation of the
alternative complement
pathway

Abnormal regulation of the
alternative complement
pathway

Light microscopy findings

Almost always a
membranoproliferative
glomerulonephritis pattern

Any pattern

Immunofluorescence findings

Dominant C3 staining

Dominant C3 staining

Electron microscopy

Linear electron dense material
within in the glomerular
basement membrane
(intramembranous)

Subendothelial, subepithelial
and/or mesangial electrondense deposits ;
Lighter density deposits

Dense deposits
Age of affected

Children and young adults;
over half will be < 16 years of
age at diagnosis.

Children and young adults;
about a quarter will be < 16
years of age at diagnosis.

C3 nephritic factor

Present 80% of the time

Present 40% of the time

Serum C3 level

>80% have low C3 levels

Approx. 50% have low C3
levels

Soluble C5b-9 level

Elevated in 9%

Elevated in 50%

Pathological gene variant

Identified in 25%

Identified in 25%

Dysregulation of alternative

Favors dysregulation of the

Favors dysregulation of the

pathway convertase

C3 convertase

C5 convertase

Extrarenal abnormalities

Drusen deposition in Bruch’s
membrane of the retina
(macular deposits)

Risk of end stage kidney
disease (ESKD)

Approx. 70% progress to
ESKD

Approx. 35% progress to
ESKD

Risk of recurrence after
kidney transplant

>50% (100% in some studies)

>50%

Presentation
The presentation of C3Gn is variable, but urine abnormalities are always present. Most
patients with C3Gn present with nephrotic range proteinuria and/or nephrotic syndrome and
hematuria. Cases presenting with subnephrotic range proteinuria or isolated gross hematuria
have been reported. The clinician cannot use serum C3 levels or other blood work as a
discerning factor from other forms of GN.3 Therefore, a kidney biopsy is required to establish the
diagnosis.5 Although most biopsies of C3Gn show a membranoproliferative pattern, this is not
required. Immunofluorescence (IF) must show dominant C3 glomerular staining in the
mesangium and capillary loops that is at least 2+ stronger than other IF stains.2 Electron
microscopy helps differentiate from DDD with C3Gn, with the latter showing lighter mesangial,
subendothelial, or epithelial deposits rather than intramembranous linear dense deposits
diagnostic of DDD.
Diagnosis and Patient Management
C3Gn is a rare disease with an incidence of 1-2 million/year (Table 2).5 Therefore, due to
lack of clinical experience, a standard causative work up/approach cannot be recommended.
However, based upon our current understanding of the pathophysiology (over activity of the

alternative complement pathway) evaluation may require genetic testing for mutations in
alternative complement proteins and measurement of autoantibodies (Table 3).3,7
Table 2. Incidence of Pediatric Nephrology Conditions
Disease/Condition

Incidence

C3 Glomerulonephritis

1-2 per million

Dense Deposit Disease

1-2 per million

Autosomal Dominant
Polycystic Kidney Disease

1 per 1,000

Autosomal Recessive
Polycystic Kidney Disease

1 per 40,000

Immunoglobulin A
Nephropathy

3 per 100,000

Nephrotic Syndrome

4 per 100,000

Pediatric End Stage Kidney
Disease

10 per million

Posterior Urethral Valves

1 per 10,000

Table 3. Considerations for the Cause of C3 Glomerulonephritis
Genetic Mutations

C3, CD46 (membrane cofactor protein), CFB,
CFH, CFHR1, CFHR2, CFHR3, CFHR4,
CFHR5, CFI

Autoantibodies

C3 nephritic factor (anti-complement factor
C3bBb), anti-complement factor H, anticomplement factor B, anti-complement factor
C3b

A standard and effective treatment is not available (Table 4). A coherent argument can be
made for targeting autoantibody (C3NF) generation and/or utilizing drugs and procedures (such

as therapeutic plasma exchange) that dampen the alternative pathway activity.5,6 Assessing the
efficacy of any one therapy is difficult due to the inclusion of patients with membranoproliferative
glomerulonephritis type 1 (which includes both C3 glomerulonephritis and immunoglobulin and
immune complex glomerulonephritis) in many studies.5 Further, reports of efficacy from
single/small case series show promising results but are subject to publication bias with the nonresponders never reported.
Table 4. Considerations for the Treatment of C3 Glomerulopathies: Dense Deposit Disease
versus C3 Glomerulonephritis.
Therapy

Dense Deposit Disease

C3 Glomerulonephritis

Glucocorticoids

No benefit

Possible benefit

Eculizumab

Possible benefit

Possible benefit

Plasma Exchange

Possible benefit

Possible benefit

Plasma Infusion

Possible benefit

No experience reported

Calcinuerin Inhibitors

No benefit

Possible benefit

Mycophenolate Mofetil

No benefit

Possible benefit

Rituximab

No benefit

Possible benefit

Greater awareness of this “new” disease entity will facilitate diagnosis and potential
enrollment in study registries and prospective studies evaluating differentiating clinical
parameters and therapies. Due to the rareness of C3Gn, this approach will be necessary to
help inform best clinical practice.
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